Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pharm Pract. 2014 Oct;27(5):461-5. doi: 10.1177/0897190014546101. Epub 2014 Aug 14.

Angioedema related to Angiotensin inhibitors.

Author information

1
Lexington VA Medical Center, Lexington, KY, USA.
2
University of Virginia Health System, Charlottesville, VA, USA.
3
University of Kentucky HealthCare, Gill Heart Institute, UK College of Pharmacy, Lexington, KY, USA temaca2@email.uky.edu.

Abstract

Angiotensin inhibitors have been extensively evaluated in clinical trials and have demonstrated significant reductions in morbidity and mortality following myocardial infarction and stroke, as well as in patients with heart failure or who are at risk of cardiovascular disease. Further, both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are frequently prescribed for the treatment of hypertension and to preserve renal function in patients with diabetes mellitus and chronic kidney disease. Angioedema is a known, but rare, adverse effect of ACEIs and ARBs. Therefore, it is important for clinicians to have a thorough understanding of risks and benefits of prescribing these medications, particularly in patients with a history of angioedema. This review describes the literature evaluating the incidence and cross-reactivity of angioedema with ACEIs and ARBs in order to provide guidance for clinical decision making.

KEYWORDS:

angioedema; angiotensin converting enzyme inhibitors (ACEI); angiotensin receptor blockers (ARBs); bradykinin; renin-angiotensin-aldosterone system (RAAS) blockade

PMID:
25124378
DOI:
10.1177/0897190014546101
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center